In January 2026, MEDIPOST Inc., the U.S. affiliate of South Korea‑based regenerative medicine and biotechnology company MEDIPOST Co., Ltd., successfully closed a $140 million funding round aimed at accelerating late-stage clinical development and operational growth. This capital infusion was led by Skylake Equity Partners and Crescendo Equity Partners, with participation from a leading Korean growth equity fund. The funds are intended to support MEDIPOST’s anticipated Phase III clinical trial of its allogeneic, umbilical cord blood-derived mesenchymal stem cell therapy for symptomatic cartilage defects in knee osteoarthritis, as well as expansion of its scientific, manufacturing, and infrastructure capabilities. [Read more…]